<?xml version='1.0' encoding='utf-8'?>
<document id="24770989"><sentence text="A plasma concentration of α-ketoglutarate influences the kinetic interaction of ligands with organic anion transporter 1."><entity charOffset="26-41" id="DDI-PubMed.24770989.s1.e0" text="α-ketoglutarate" /></sentence><sentence text="The purpose of the present study was to determine whether a physiologic plasma concentration of α-ketoglutarate (αKG) influences the kinetic interaction of ligands with organic anion transporter 1 (OAT1)"><entity charOffset="96-111" id="DDI-PubMed.24770989.s2.e0" text="α-ketoglutarate" /><entity charOffset="113-116" id="DDI-PubMed.24770989.s2.e1" text="αKG" /><pair ddi="false" e1="DDI-PubMed.24770989.s2.e0" e2="DDI-PubMed.24770989.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s2.e0" e2="DDI-PubMed.24770989.s2.e1" /></sentence><sentence text=" The effect of extracellular αKG on the kinetics of para-aminohippurate (PAH) and cidofovir transport was examined along with its effect on the potency of 10 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and β-lactam antibiotics) to inhibit OAT1 expressed in Chinese hamster ovary cells"><entity charOffset="52-71" id="DDI-PubMed.24770989.s3.e0" text="para-aminohippurate" /><entity charOffset="73-76" id="DDI-PubMed.24770989.s3.e1" text="PAH" /><entity charOffset="82-91" id="DDI-PubMed.24770989.s3.e2" text="cidofovir" /><entity charOffset="253-267" id="DDI-PubMed.24770989.s3.e3" text="angiotensin II" /><entity charOffset="29-42" id="DDI-PubMed.24770989.s3.e4" text="αKG" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e4" e2="DDI-PubMed.24770989.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e4" e2="DDI-PubMed.24770989.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e4" e2="DDI-PubMed.24770989.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e4" e2="DDI-PubMed.24770989.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e4" e2="DDI-PubMed.24770989.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e0" e2="DDI-PubMed.24770989.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e0" e2="DDI-PubMed.24770989.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e0" e2="DDI-PubMed.24770989.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e0" e2="DDI-PubMed.24770989.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e1" e2="DDI-PubMed.24770989.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e1" e2="DDI-PubMed.24770989.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e1" e2="DDI-PubMed.24770989.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e2" e2="DDI-PubMed.24770989.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s3.e2" e2="DDI-PubMed.24770989.s3.e3" /></sentence><sentence text=" Extracellular αKG competitively inhibited PAH and cidofovir transport with Ki values (∼5 μM) approximating its unbound plasma concentration (determined by equilibrium dialysis)"><entity charOffset="51-60" id="DDI-PubMed.24770989.s4.e0" text="cidofovir" /><entity charOffset="15-23" id="DDI-PubMed.24770989.s4.e1" text="αKG" /><entity charOffset="43-51" id="DDI-PubMed.24770989.s4.e2" text="PAH" /><pair ddi="false" e1="DDI-PubMed.24770989.s4.e1" e2="DDI-PubMed.24770989.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s4.e1" e2="DDI-PubMed.24770989.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s4.e1" e2="DDI-PubMed.24770989.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s4.e2" e2="DDI-PubMed.24770989.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s4.e2" e2="DDI-PubMed.24770989.s4.e0" /></sentence><sentence text=" When PAH was the substrate, extracellular αKG (5 μM) significantly increased IC50 values for some inhibitors (up to 4-fold), such as probenecid, but not for others (an inhibitor-dependent effect)"><entity charOffset="134-144" id="DDI-PubMed.24770989.s5.e0" text="probenecid" /><entity charOffset="43-52" id="DDI-PubMed.24770989.s5.e1" text="αKG" /><entity charOffset="6-15" id="DDI-PubMed.24770989.s5.e2" text="PAH" /><pair ddi="false" e1="DDI-PubMed.24770989.s5.e2" e2="DDI-PubMed.24770989.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24770989.s5.e2" e2="DDI-PubMed.24770989.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s5.e2" e2="DDI-PubMed.24770989.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s5.e1" e2="DDI-PubMed.24770989.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24770989.s5.e1" e2="DDI-PubMed.24770989.s5.e0" /></sentence><sentence text=" For some inhibitors, a significant increase in IC50 value was observed when cidofovir was the substrate, but not PAH (a substrate-dependent effect)"><entity charOffset="77-86" id="DDI-PubMed.24770989.s6.e0" text="cidofovir" /><entity charOffset="114-122" id="DDI-PubMed.24770989.s6.e1" text="PAH" /><pair ddi="false" e1="DDI-PubMed.24770989.s6.e0" e2="DDI-PubMed.24770989.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24770989.s6.e0" e2="DDI-PubMed.24770989.s6.e1" /></sentence><sentence text=" A significant increase in IC50 value was also observed for inhibition of PAH transport by probenecid in renal basolateral membrane vesicles (5"><entity charOffset="74-76" id="DDI-PubMed.24770989.s7.e0" text="PAH" /></sentence><sentence text="2-fold)" /><sentence text=" The substrate- and inhibitor-dependent effect of extracellular αKG on ligand interactions with OAT1 highlights the complexity of the OAT1 ligand-binding surface"><entity charOffset="64-66" id="DDI-PubMed.24770989.s9.e0" text="αKG" /></sentence><sentence text=" The effect of extracellular αKG on the potency of OAT1 inhibition should be considered when assessing drug-drug interaction potential at the transporter"><entity charOffset="29-31" id="DDI-PubMed.24770989.s10.e0" text="αKG" /></sentence><sentence text=" " /></document>